claritromycine
J - Antiinfectives For Systemic Use -> J01 - Antibacterials For Systemic Use -> J01F - Macrolides, Lincosamides And Streptogramins -> J01FA - Macrolides -> J01FA09 - Clarithromycin
Administration category:
Free
Medicine group:
antibacterial
Brand name:
Klacid
Safety margins
| Weight | ROA | Dosage | |
|---|---|---|---|
|
ROA: po |
Dosage: min. 250mg 2 dd to max. 500mg 2 dd |
||
|
Comments:
Maximale dagdosis bij CF: 1000 mg 2 dd. Er is ook een preparaat met gereguleerde afgifte: 500 mg 1x per dag tijdens het eten, zo nodig verhogen tot 1000 mg 1x per dag. |
|||
Dosage for "I" sensitivity
| Weight | ROA | Load | Dosage |
|---|---|---|---|
|
ROA: po |
Load: - |
Dosage: 500mg 2 dd |
Kidney function
| ROA | GFR | Dosage | Interval | Comments |
|---|---|---|---|---|
| ROA: po | ||||
|
GFR: 10 - 30 |
Dosage: 50% |
|||
Renal elimination:
20-40%
Dosage:
dependent on kidney function
Renal function-replacement therapy
CAPD: 50% van de normale keerdosis bij gelijkblijvend doseringsinterval
Hemo dialysis: 50% van de normale keerdosis bij gelijkblijvend doseringsinterval
CAV / VVHD: 50% van de normale keerdosis bij gelijkblijvend doseringsinterval
Interactions
| Interaction with (ATC): | Expected effect: |
|---|---|
|
Interaction with (ATC): N03AF01 - Carbamazepine |
Expected effect: verhoging plasmaconcentratie carbamazepine |
|
Interaction with (ATC): L04AD01 - Ciclosporin |
Expected effect: verhoging ciclosporineconcentratie in volbloed |
|
Interaction with (ATC): C01AA05 - Digoxin |
Expected effect: verhoging plasmaconcentratie digoxine |
|
Interaction with (ATC): L04AD02 - Tacrolimus |
Expected effect: verhoging plasmaconcentratie tacrolimus |
|
Interaction with (ATC): R03DA04 - Theophylline |
Expected effect: verhoging plasmaconcentratie theofylline |
|
Interaction with (ATC): R06AX12 - Terfenadine |
Expected effect: toename cardiotoxiciteit |
|
Interaction with (ATC): A03FA02 - Cisapride |
Expected effect: toename cardiotoxiciteit |
|
Interaction with (ATC): C01BA03 - Disopyramide |
Expected effect: toename cardiotoxiciteit |
|
Interaction with (ATC): J05AE - Protease Inhibitors |
Expected effect: verhoging plasmaconcentratie proteaseremmers en claritromycine |
Pregnancy
Due to the expiration of the alphanumeric classification for use in pregnancy and lactation, reference is made to the current, online information of the Teratology Information Service (TIS) of LAREB:
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Zwangerschap#TOC_Middelen_bij6
- http://www.lareb.nl//Teratologie/Naslagwerk-GZB/GZB---Borstvoeding#TOC_Middelen_bij16
For individual advice, consult an expert on site.
Metadata
Swab vid: M-1260.6
Updated: 12/24/2024 - 15:59
Status: Published